Through our wholly-owned subsidiary, Antigen Express, Inc. ("Antigen"), Generex has undertaken work on immunotherapy research incorporating proprietary vaccine formulations.

We recently acquired Hema Diagnostic Systems, Inc. (Hema) in the business of developing, manufacturing, and distributing in-vitro medical diagnostics for infectious diseases administered at the point-of-care level with results as soon as 10-15 minutes. Hema has an expanding line of Rapid Diagnostic Tests (RDTs), known as RAPID 1-2-3 HEMA Express I and II®, for the infectious diseases such as Human Immunodeficiency Virus (HIV) - 1/2 w/p24Ab, tuberculosis-XT, malaria, hepatitis, syphilis, typhoid, dengue, and others in development.

Hema Diagnostic Systems (HDS) is a subsidiary of Generex. HDS is a manufacturer of in-vitro medical diagnostic devices for both point of care and laboratory-based tests, primarily for infectious diseases. 

Strategically, the Company’s mission has been to develop, manufacture and market a series of diagnostic tests that yields repeatable and reliable test results for an antibody or antigenic response to a specific disease in such samples as whole blood, plasma, or serum. Currently, our product line includes such tests for infectious diseases such as HIV, Syphilis, Tuberculosis, Malaria, Hepatitis-B, and Hepatitis-C.

HDS has developed rapid diagnostic assays capable of delivering test results within 10-15 minutes, and requiring a small amount of whole blood usually taken from a finger stick; serum or plasma samples are approved for use when performing the test in a laboratory. HDS has produced and validated multiple diagnostic test strips, each developed for a particular disease and carefully produced following strict ISO 13485, and ISO 9001 standards. Our test strips are assembled into any of the two available delivery devices, the RAPID 1-2-3® HEMA EXPRESS®, and the RAPID 1-2-3® HEMA CASSETTE. Any of these two formats facilitate the rapid and easy use of the diagnostic in the field, clinic or office.
Antigen Express, Inc. is a wholly owned subsidiary of Generex. Antigen Express is a platform and product-based company developing proprietary vaccine formulations for large, unmet medical needs. Our focus is on stimulating critical members of the immune response, known as T helper cells.

The technology allows for antigen-specific stimulation or suppression of a T-helper response to virtually any antigen of known pathogenic potential. Consequential, Antigen Express is building a deep pipeline of therapeutics aimed at a variety of major diseases, including cancer, infectious diseases and autoimmune-based syndromes.

Antigen Express therapies are based on highly selective modulation of the immune response, in contrast to most current immunomodulation strategies that are in general non-specific. This lack of specificity is the prime source for unwanted side effects. The therapies developed at Antigen Express intervene at the critical stage of antigen presentation to modulate the immune response. This targeted approach results in a potent up or down regulation of critical members of the immune system.

The technologies developed at Antigen Express are novel and highly complementary to existing approaches of immune modification. Therefore, the company is uniquely positioned to develop partnerships where Antigen Express technology enhances or augments the corporate partners’ technology or product portfolios.